Подписаться
Christine M. Lovly, MD, PhD
Christine M. Lovly, MD, PhD
Associate Professor of Medicine, Vanderbilt University Medical Center
Подтвержден адрес электронной почты в домене vumc.org
Название
Процитировано
Процитировано
Год
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ...
Journal of clinical oncology 30 (8), 863-870, 2012
19372012
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ...
Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017
11812017
Mechanisms of receptor tyrosine kinase activation in cancer
Z Du, CM Lovly
Molecular cancer 17, 1-13, 2018
8372018
NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines
DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ...
Journal of the National Comprehensive Cancer Network 19 (3), 254-266, 2021
7862021
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ...
Journal of the National Comprehensive Cancer Network 20 (5), 497-530, 2022
7012022
NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines
DS Ettinger, DE Wood, C Aggarwal, DL Aisner, W Akerley, JR Bauman, ...
Journal of the National Comprehensive Cancer Network 17 (12), 1464-1472, 2019
6672019
Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
D Westover, J Zugazagoitia, BC Cho, CM Lovly, L Paz-Ares
Annals of oncology 29, i10-i19, 2018
5642018
Acquired Resistance to KRASG12C Inhibition in Cancer
MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ...
New England Journal of Medicine 384 (25), 2382-2393, 2021
5562021
First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers
N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ...
Journal of Clinical Oncology 37 (12), 992, 2019
5382019
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ...
Nature communications 7 (1), 10582, 2016
5062016
NCCN guidelines insights: non–small cell lung cancer, version 5.2018
DS Ettinger, DL Aisner, DE Wood, W Akerley, J Bauman, JY Chang, ...
Journal of the National Comprehensive Cancer Network 16 (7), 807-821, 2018
5022018
Non–small cell lung cancer, version 2.2013
DS Ettinger, W Akerley, H Borghaei, AC Chang, RT Cheney, LR Chirieac, ...
Journal of the National Comprehensive Cancer Network 11 (6), 645-653, 2013
4962013
Targeted next generation sequencing identifies markers of response to PD-1 blockade
DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ...
Cancer immunology research 4 (11), 959-967, 2016
4712016
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ...
Annals of oncology 29 (4), 959-965, 2018
4592018
NCCN guidelines insights: non–small cell lung cancer, version 4.2016
DS Ettinger, DE Wood, W Akerley, LA Bazhenova, H Borghaei, ...
Journal of the National Comprehensive Cancer Network 14 (3), 255-264, 2016
4562016
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
YY Janjigian, EF Smit, HJM Groen, L Horn, S Gettinger, DR Camidge, ...
Cancer discovery 4 (9), 1036-1045, 2014
4282014
Non–small cell lung cancer
DS Ettinger, W Akerley, H Borghaei, AC Chang, RT Cheney, LR Chirieac, ...
Journal of the National Comprehensive Cancer Network 10 (10), 1236-1271, 2012
4262012
Burnout and career satisfaction among US oncologists
TD Shanafelt, WJ Gradishar, M Kosty, D Satele, H Chew, L Horn, B Clark, ...
Journal of Clinical Oncology 32 (7), 678, 2014
4172014
Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)
SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, ...
Journal of Clinical Oncology 39 (6), 619-630, 2021
4122021
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung …
YK Chae, A Arya, W Iams, MR Cruz, S Chandra, J Choi, F Giles
Journal for immunotherapy of cancer 6, 1-27, 2018
4102018
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20